LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

SpringWorks Therapeutics Inc

Avatud

SektorTervishoid

46.1 -0.07

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

46.09

Max

46.19

Põhinäitajad

By Trading Economics

Sissetulek

-5.9M

-83M

Müük

-12M

49M

Aktsiakasum

-1.11

Kasumimarginaal

-169.468

Töötajad

368

EBITDA

-23M

-80M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+27.11% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. aug 2025

Turustatistika

By TradingEconomics

Turukapital

5.6M

3.5B

Eelmine avamishind

46.17

Eelmine sulgemishind

46.1

Uudiste sentiment

By Acuity

67%

33%

339 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

SpringWorks Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. apr 2025, 11:25 UTC

Omandamised, ülevõtmised, äriostud

Germany's Merck to Buy SpringWorks for $3.9 Billion -- Update

28. apr 2025, 06:41 UTC

Omandamised, ülevõtmised, äriostud

Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal

11. veebr 2025, 07:03 UTC

Omandamised, ülevõtmised, äriostud

Germany's Merck in Talks to Buy SpringWorks Therapeutics

10. veebr 2025, 16:38 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

28. apr 2025, 15:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Merck KGaA's $3.9B SpringWorks Therapeutics Buy Underwhelms -- Market Talk

28. apr 2025, 09:20 UTC

Kuumad aktsiad

Stocks to Watch Monday: DoorDash, Merck, Spirit AeroSystems, Airbus -- WSJ

28. apr 2025, 06:06 UTC

Omandamised, ülevõtmised, äriostud

Germany's Merck: Acquisition Will Strengthen Merck Healthcare Presence in U.S.

28. apr 2025, 06:05 UTC

Omandamised, ülevõtmised, äriostud

Germany's Merck: Planned Acquisition Will Immediately Add Revenue, Accelerate Growth

28. apr 2025, 06:05 UTC

Omandamised, ülevõtmised, äriostud

Germany's Merck: Deal Is for Purchase Price of $47 a Share in Cash

28. apr 2025, 06:04 UTC

Omandamised, ülevõtmised, äriostud

Germany's Merck to Buy SpringWorks for About $3.9B

28. apr 2025, 06:02 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Germany's Merck to Buy SpringWorks Therapeutics

24. apr 2025, 22:51 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24. apr 2025, 20:54 UTC

Omandamised, ülevõtmised, äriostud

Merck KGaA: No Final Decision Has Been Taken; No Legally Binding Agreement Has Been Entered Into

24. apr 2025, 20:50 UTC

Omandamised, ülevõtmised, äriostud

Merck KGaA Confirms Late-Stage Discussions With SpringWorks Therapeutics on Potential Acquisition for About 47c a Share

24. apr 2025, 19:05 UTC

Omandamised, ülevõtmised, äriostud

Merck KGaA Expected to Pay Close to $47 a Share for SpringWorks, Sources Say -- WSJ

24. apr 2025, 19:05 UTC

Omandamised, ülevõtmised, äriostud

Merck KGaA, SpringWorks Deal Expected to Be Finalized as Soon as Monday, Sources Say -- WSJ

24. apr 2025, 19:05 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- WSJ

24. apr 2025, 19:05 UTC

Omandamised, ülevõtmised, äriostud

Merck KGaA Nears Roughly $3.5 Billion Takeover of SpringWorks Therapeutics, Sources Say -- WSJ

11. veebr 2025, 10:54 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

11. veebr 2025, 10:52 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Võrdlus sarnastega

Hinnamuutus

SpringWorks Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

27.11% tõus

12 kuu keskmine prognoos

Keskmine 58.75 USD  27.11%

Kõrge 84 USD

Madal 47 USD

Põhineb 8 Wall Streeti analüütiku instrumendi SpringWorks Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

3

Osta

5

Hoia

0

Müü

Tehniline skoor

By Trading Central

46.18 / 46.305Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Very Strong Bullish Evidence

Sentiment

By Acuity

339 / 382 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.